Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment

This study has been completed.
Information provided by:
Meir Medical Center Identifier:
First received: May 3, 2010
Last updated: June 15, 2010
Last verified: June 2010
The aim of this study was to evaluate the effect of dehydroepiandrosterone supplementation on in vitro fertilization performance and outcome among poor-responder patient.

Condition Intervention
Ovarian Stimulation
Drug: dehydroepiandrosterone crystalline fine powder

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • peak estradiol level.
  • number of retrieved oocytes.
  • Embryos that were graded as a top quality (according to the number of cells and percent of fragmentation)
  • number of embryos reserved for transfer.

Secondary Outcome Measures:
  • pregnancy rate.
  • live birth rate.

Study Start Date: January 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DHEA supplementation
DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
Drug: dehydroepiandrosterone crystalline fine powder
No Intervention: only induction of ovulation by same long protocol without DHEA


Ages Eligible for Study:   18 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • previous poor response to ovarian stimulation in IVF.

Exclusion Criteria:

  • patients over the age of 42
  • patients who received DHEA at any time.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01145144

Meir Medical center IVF unit
kfar Saba, Israel
Meir Medical Center
Kfar Sava, Israel
Sponsors and Collaborators
Meir Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Adriam Shulman, IVF Unit Meir Medical Center Identifier: NCT01145144     History of Changes
Other Study ID Numbers: mmc07204-2006ctil
Study First Received: May 3, 2010
Last Updated: June 15, 2010

Keywords provided by Meir Medical Center:
IVF outcome
long protocol IVF
recombinant LH
embryo quality
pregnancy rate
live birth rate
poor response to ovarian stimulation

Additional relevant MeSH terms:
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs processed this record on May 22, 2017